Unknown

Dataset Information

0

I-SPY COVID adaptive platform trial for COVID-19 acute respiratory failure: rationale, design and operations.


ABSTRACT:

Introduction

The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges of the ISPY COVID-19 trial during the first phase of trial activity from April 2020 until December 2021.

Methods and analysis

The ISPY COVID-19 Trial is a multicentre open-label phase 2 platform trial in the USA designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID-19 Trial network includes academic and community hospitals with significant geographical diversity across the country. Enrolled patients are randomised to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical design uses a Bayesian model with 'stopping' and 'graduation' criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrols to a maximum of 125 patients per arm and is compared with concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrolment and adaptation of the trial design are ongoing.

Ethics and dissemination

ISPY COVID-19 operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer-reviewed medical journals.

Trial registration number

NCT04488081.

SUBMITTER: Files DC 

PROVIDER: S-EPMC9170797 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalised with severe COVID-19. The Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis (ISPY COVID-19 trial) was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation and challenges  ...[more]

Similar Datasets

| S-EPMC6097170 | biostudies-literature
| S-EPMC9049563 | biostudies-literature
| S-EPMC7328186 | biostudies-literature
| S-EPMC9981330 | biostudies-literature
| S-EPMC5341700 | biostudies-literature
| S-EPMC11631246 | biostudies-literature
| S-EPMC8711313 | biostudies-literature
| S-EPMC9029212 | biostudies-literature
| S-EPMC8443914 | biostudies-literature
| S-EPMC3511776 | biostudies-literature